Mining Retrospective Data for Virtual Prospective Drug Repurposing: L-DOPA and Age-related Macular Degeneration

American Journal of Medicine

Volumn 129, Issue 3, 2016, Pages 292-298

  Brilliant, Murray H ^a   Vaziri, Kamyar ^b   Connor, Thomas B ^c   Schwartz, Stephen G ^b   Carroll, Joseph J ^c   McCarty, Catherine A ^d   Schrodi, Steven J ^a   Hebbring, Scott J ^a   Kishor, Krishna S ^b   Flynn, Harry W ^b   Moshfeghi, Andrew A ^e   Moshfeghi, Darius M ^f   Fini, M Elizabeth ^e   McKay, Brian S ^g,h  

^a MARSHFIELD CLINIC   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c MEDICAL COLLEGE OF WISCONSIN   (United States)

^d ESSENTIA INSTITUTE OF RURAL HEALTH   (United States)

^e UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^f STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^h UNIVERSITY OF ARIZONA   (United States)

Author keywords

Age related macular degeneration (AMD); GPR143; L DOPA; Movement disorder; Parkinson's disease; Retinal pigment epithelium (RPE); Retrospective study

Indexed keywords

LEVODOPA; ANTIPARKINSON AGENT; EYE PROTEIN; GPR143 PROTEIN, HUMAN; MEMBRANE PROTEIN;

AGE RELATED MACULAR DEGENERATION; ARTICLE; DATA MINING; DRUG REPOSITIONING; HUMAN; INCIDENCE; MEDICAL RECORD REVIEW; ONSET AGE; OUTPATIENT; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; AGE DISTRIBUTION; AGED; COHORT ANALYSIS; MACULAR DEGENERATION; PHYSIOLOGY; UNITED STATES;

AGE DISTRIBUTION; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; COHORT STUDIES; DATA MINING; EYE PROTEINS; HUMANS; LEVODOPA; MACULAR DEGENERATION; MEMBRANE GLYCOPROTEINS; RETROSPECTIVE STUDIES; UNITED STATES;

EID: 84958047136     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2015.10.015     Document Type: Article

References (47)

1. Y.Y. Li, and S.J. Jones Drug repositioning for personalized medicine Genome Med 4 2012 27
2. D.M. Roden, H. Xu, J.C. Denny, and R.A. Wilke Electronic medical records as a tool in clinical pharmacology: opportunities and challenges Clin Pharmacol Ther 91 2012 1083 1086
3. S. Resnikoff, D. Pascolini, D. Etya'ale, and et al. Global data on visual impairment in the year 2002 Bull World Health Organ 82 2004 844 851
4. J. Ambati, B.K. Ambati, S.H. Yoo, S. Ianchulev, and A.P. Adamis Age-related macular degeneration: etiology, pathogenesis, and therapeutic strategies Surv Ophthalmol 48 2003 257 293
5. J.T. Handa New molecular histopathologic insights into the pathogenesis of age-related macular degeneration Int Ophthalmol Clin 47 2007 15 50
6. R.D. Jager, W.F. Mieler, and J.W. Miller Age-related macular degeneration N Engl J Med 358 2008 2606 2617
7. J. Ngondi, F. Ole-Sempele, A. Onsarigo, and et al. Prevalence and causes of blindness and low vision in southern Sudan PLoS Med 3 2006 e477
8. S.B. Bressler, B. Munoz, S.D. Solomon, S.K. West Salisbury Eye Evaluation (SEE) Study Team Racial differences in the prevalence of age-related macular degeneration: the Salisbury Eye Evaluation (SEE) Project Arch Ophthalmol 126 2008 241 245
9. D.B. Rein Vision problems are a leading source of modifiable health expenditures Invest Ophthalmol Vis Sci 54 2013 ORSF18 ORSF22
10. L.D. Wagner, and D.B. Rein Attributes associated with eye care use in the United States: a meta-analysis Ophthalmology 120 2013 1497 1501
11. K.D. Frick, S.M. Kymes, P.P. Lee, and et al. The cost of visual impairment: purposes, perspectives, and guidance Invest Ophthalmol Vis Sci 51 2010 1801 1805
12. D.B. Rein, J.S. Wittenborn, X. Zhang, and et al. Forecasting age-related macular degeneration through the year 2050: the potential impact of new treatments Arch Ophthalmol 127 2009 533 540
13. D.B. Rein, J.B. Saaddine, J.S. Wittenborn, and et al. Technical appendix: cost-effectiveness of vitamin therapy for age-related macular degeneration Ophthalmology 114 2007 e13 e20
14. D.B. Rein, J.B. Saaddine, J.S. Wittenborn, and et al. Cost-effectiveness of vitamin therapy for age-related macular degeneration Ophthalmology 114 2007 1319 1326
15. D.B. Rein, P. Zhang, K.E. Wirth, and et al. The economic burden of major adult visual disorders in the United States Arch Ophthalmol 124 2006 1754 1760
16. M.G. Maguire Comparing treatments for age-related macular degeneration: safety, effectiveness and cost LDI Issue Brief 17 2012 1 4
17. R. Klein, B.E. Klein, M.D. Knudtson, and et al. Prevalence of age-related macular degeneration in 4 racial/ethnic groups in the multi-ethnic study of atherosclerosis Ophthalmology 113 2006 373 380
18. R. Klein, C.F. Chou, B.E. Klein, X. Zhang, S.M. Meuer, and J.B. Saaddine Prevalence of age-related macular degeneration in the US population Arch Ophthalmol 129 2011 75 80
19. Age-Related Eye Disease Study Research Group A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS report no. 9 Arch Ophthalmol 119 2001 1439 1452
20. Writing Group for the AREDS2 Research Group D.E. Bonds, M. Harrington, and et al. Effect of long-chain omega-3 fatty acids and lutein + zeaxanthin supplements on cardiovascular outcomes: results of the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial JAMA Intern Med 174 2014 763 771
21. B. Heimes, A. Lommatzsch, M. Zeimer, and et al. Long-term visual course after anti-VEGF therapy for exudative AMD in clinical practice evaluation of the German reinjection scheme Graefes Arch Clin Exp Ophthalmol 249 2011 639 644
22. C.H. Meyer, and F.G. Holz Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab Eye (Lond) 25 2011 661 672
23. J.L. Kovach, S.G. Schwartz, H.W. Flynn Jr., and I.U. Scott Anti-VEGF treatment strategies for wet AMD J Ophthalmol 2012 2012 786870
24. W.M. Amoaku, U. Chakravarthy, R. Gale, and et al. Defining response to anti-VEGF therapies in neovascular AMD Eye (Lond) 29 2015 1397 1398
25. J.K. Schmier, M.T. Halpern, D.W. Covert, J. Delgado, and S. Sharma Impact of visual impairment on service and device use by individuals with age-related macular degeneration (AMD) Disabil Rehabil 28 2006 1331 1337
26. D.R. Levinson Medicare Payments for Drugs Used to Treat Wet Age-Related Macular Degeneration (OEI-03-10) 2012 US Department of Health and Human Services, Office of The Inspector General Washington, DC 1 22
27. V.M. Lopez, C.L. Decatur, W.D. Stamer, R.M. Lynch, and B.S. McKay L-DOPA is an endogenous ligand for OA1 PLoS Biol 6 2008 e236
28. T. Falk, N.R. Congrove, S. Zhang, A.D. McCourt, S.J. Sherman, and B.S. McKay PEDF and VEGF-A output from human retinal pigment epithelial cells grown on novel microcarriers J Biomed Biotechnol 2012 2012 278932
29. C.A. McCarty, R.A. Wilke, P.F. Giampietro, S.D. Wesbrook, and G.M. Caldwell Marshfield Clinic Personalized Medicine Research Project (PRMP): design, methods and recruitment for a large population-based biobank Personalized Med 2 2005 49 79
30. R.T. Greenlee Measuring disease frequency in the Marshfield Epidemiologic Study Area (MESA) Clin Med Res 1 2003 273 280
31. J.M. Seddon, W.C. Willett, F.E. Speizer, and S.E. Hankinson A prospective study of cigarette smoking and age-related macular degeneration in women JAMA 276 1996 1141 1146
32. M. van der Mark, P.C. Nijssen, J. Vlaanderen, and et al. A case-control study of the protective effect of alcohol, coffee, and cigarette consumption on Parkinson disease risk: time-since-cessation modifies the effect of tobacco smoking PloS One 9 2014 e95297
33. E.L. Thacker, E.J. O'Reilly, M.G. Weisskopf, and et al. Temporal relationship between cigarette smoking and risk of Parkinson disease Neurology 68 2007 764 768
34. S.C. Tomany, J.J. Wang, R. Van Leeuwen, and et al. Risk factors for incident age-related macular degeneration: pooled findings from 3 continents Ophthalmology 111 2004 1280 1287
35. O. Rascol, D.J. Brooks, A.D. Korczyn, P.P. De Deyn, C.E. Clarke, and A.E. Lang A five-year study of the incidence of dyskinesia in patients with early Parkinson's disease who were treated with ropinirole or levodopa N Engl J Med 342 2000 1484 1491
36. A. Machalinska, K. Safranow, K. Mozolewska-Piotrowska, V. Dziedziejko, and D. Karczewicz PEDF and VEGF plasma level alterations in patients with dry form of age-related degeneration-a possible link to the development of the disease Klin Oczna 114 2012 115 120
37. V. Haurigot, P. Villacampa, A. Ribera, and et al. Long-term retinal PEDF overexpression prevents neovascularization in a murine adult model of retinopathy PloS One 7 2012 e41511
38. B.O. Boehm, G. Lang, O. Volpert, and et al. Low content of the natural ocular anti-angiogenic agent pigment epithelium-derived factor (PEDF) in aqueous humor predicts progression of diabetic retinopathy Diabetologia 46 2003 394 400
39. C.J. Locke, N.R. Congrove, W.M. Dismuke, T.J. Bowen, W.D. Stamer, and B.S. McKay Controlled exosome release from the retinal pigment epithelium in situ Exp Eye Res 129 2014 1 4
40. J.J. Weiter, F.C. Delori, G.L. Wing, and K.A. Fitch Retinal pigment epithelial lipofuscin and melanin and choroidal melanin in human eyes Invest Ophthalmol Vis Sci 27 1986 145 152
41. T. Sarna, J.M. Burke, W. Korytowski, and et al. Loss of melanin from human RPE with aging: possible role of melanin photooxidation Exp Eye Res 76 2003 89 98
42. J. Tombran-Tink, S.M. Shivaram, G.J. Chader, L.V. Johnson, and D. Bok Expression, secretion, and age-related downregulation of pigment epithelium-derived factor, a serpin with neurotrophic activity J Neurosci 15 1995 4992 5003
43. M. Matsuoka, N. Ogata, T. Otsuji, T. Nishimura, K. Takahashi, and M. Matsumura Expression of pigment epithelium derived factor and vascular endothelial growth factor in choroidal neovascular membranes and polypoidal choroidal vasculopathy Br J Ophthalmol 88 2004 809 815
44. N.M. Holekamp, N. Bouck, and O. Volpert Pigment epithelium-derived factor is deficient in the vitreous of patients with choroidal neovascularization due to age-related macular degeneration Am J Ophthalmol 134 2002 220 227
45. I.A. Bhutto, D.S. McLeod, T. Hasegawa, and et al. Pigment epithelium-derived factor (PEDF) and vascular endothelial growth factor (VEGF) in aged human choroid and eyes with age-related macular degeneration Exp Eye Res 82 2006 99 110
46. M. Pons, and M.E. Marin-Castano Cigarette smoke-related hydroquinone dysregulates MCP-1, VEGF and PEDF expression in retinal pigment epithelium in vitro and in vivo PloS One 6 2011 e16722
47. M. Pons, and M.E. Marin-Castano Nicotine increases the VEGF/PEDF ratio in retinal pigment epithelium: a possible mechanism for CNV in passive smokers with AMD Invest Ophthalmol Vis Sci 52 2011 3842 3853